Impact of Switching to New ResMed Devices on Continuous Positive Airway Pressure Therapy: A Multicenter Study

Abstract

Purpose ResMed Inc. has recently developed new continuous positive airway pressure (CPAP) devices, namely the AirSense 11 series. This study aimed to determine whether new ResMed devices have a more favorable impact on CPAP therapy than previous models.

Methods This prospective multicenter study was conducted at Kyoto University Hospital, Rakuwakai Otowa Hospital, Shibata Clinic, and Hatta Medical Clinic. Patients with sleep apnea syndrome who used the previous generation of ResMed devices and switched to new ResMed devices from April 2023 to June 2024 were eligible to participate in the study. CPAP device data for one month before and after switching to new ResMed devices were downloaded using ResScan, NemLink, or f'Rens.

Results A total of 102 patients were included in this analysis. The switch from old to new ResMed devices resulted in significant decreases in median CPAP pressure and 95th percentile leak from 8.1 (6.8-9.9) cmH₂O to 7.4 (6.2-8.8) cmH₂O (p<0.0001) and from 25.2 (14.4-36.2) L/min to 21.9 (14.4-33.8) L/min (p=0.0034), respectively. The percentage of CPAP therapy used for at least 4 h increased from 86% (56.1%-94.3%) to 90% (60-100%) (p=0.0043). Meanwhile, the switch to new ResMed devices did not affect the apnea-hypopnea index (1.7 [0.9-2.9] events/h vs. 1.3 [0.7-2.6] events/h, p=0.092).

Conclusion The New ResMed device had favorable effects on CPAP therapy. The effects of different devices from the same manufacturers, as well as those from different manufacturers, on CPAP therapy should be carefully investigated.